Influence of cardiac function, inflammatory factor and matrix metalloproteinases in chronic heart failure patients with the treatment of rosuvastatin

• Main Authors: Jie Xu, Xiao-Mei Luo, Qiang Hu
• Format: Article
• Language: English
• Published: Editorial Board of Journal of Hainan Medical University 2016-05-01
• Series: Journal of Hainan Medical University
• Subjects: Rosuvastatin; Chronic heart failure; Cardiac function; Inflammatory factor; Matrix metalloproteinases
• Online Access: http://www.hnykdxxb.com/PDF/201610/8.pdf
• ISSN: 1007-1237; 1007-1237

Objective: To explore the influence of cardiac function,inflammatory factor and matrix metalloproteinases (MMP) in chronic heart failure (CHD) patients with the treatment of rosuvastatin. Methods: Chose 100 cases of CHF as the research object, they were divided into observation group and control group according to random number table method , 50 cases in each group, patients in two groups were given routine CHF treatment, on this basis, patients in the observation group were given rosuvastatin, they were treated for 6 months, compared the cardiac function indexes: left ventricular ejection fraction (LVEF), left ventricular enddiastolic diameter (LVEDD) and left ventricular end systolic diameter (LVESD), inflammatory factor: high sensitivity C-reactive protein (hs-CRP) and interleukin 6 (IL-6) and tumor necrosis factor α (TNF-α) and MMPS: MMP-2 and MMP-9 in two groups before and after treatment. Results: The levels of LVEF in observation group after treatment was significantly higher than before and the control group after treatment,the levesls of LVEDD, LVESD, hs-CRP, IL-6, TNF-α, MMP-2 and MMP-9 were significantly lower than before and the control group after treatment, the differences were statistically significant; The levels of LVEF in control group after treatment were significantly higher while the levels of LVEDD, LVESD, MMP-2 and MMP-9 were significantly lower than before the treatment, the differences were statistically significant. Conclusion: Rosuvastatin can significantly improve cardiac function in patients with CHF, it may related to its inhibitory effect of inflammation and ventricular remodeling.